Around 4:00 PM on the 13th, the first day of subscription for the public offering stock HL Genomics came to a close. The results from the first day of this subscription, conducted through KB Securities and IBK Investment Securities, are as follows.

• Number of Subscriptions: KB Securities 65,748 / IBK Investment Securities 2,785 • Equal Allocation Shares: KB Securities 4.39 shares / IBK Investment Securities 11.51 shares • Proportional Competition Rate: KB Securities 22.96:1 / IBK Investment Securities 5.20:1

According to disclosure materials, HL Genomics produces prescription drugs corresponding to active pharmaceutical ingredients among active pharmaceutical ingredients and finished pharmaceutical products.

Meanwhile, HL Genomics is scheduled to be listed on July 24. If the stock price records a 'double-double' on the day of listing, it could rise to 86,000 won, a 300% increase compared to the public offering price of 21,500 won.

[This article is intended to provide information about market trends and is not a solicitation for investment. Investment decisions and their consequences are the sole responsibility of the investor.]